493 related articles for article (PubMed ID: 25875772)
1. Circulating free DNA as biomarker and source for mutation detection in metastatic colorectal cancer.
Spindler KL; Pallisgaard N; Andersen RF; Brandslund I; Jakobsen A
PLoS One; 2015; 10(4):e0108247. PubMed ID: 25875772
[TBL] [Abstract][Full Text] [Related]
2. Clinical utility of KRAS status in circulating plasma DNA compared to archival tumour tissue from patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor therapy.
Spindler KL; Pallisgaard N; Appelt AL; Andersen RF; Schou JV; Nielsen D; Pfeiffer P; Yilmaz M; Johansen JS; Hoegdall EV; Jakobsen A; Jensen BV
Eur J Cancer; 2015 Nov; 51(17):2678-85. PubMed ID: 26508156
[TBL] [Abstract][Full Text] [Related]
3. Changes in mutational status during third-line treatment for metastatic colorectal cancer--results of consecutive measurement of cell free DNA, KRAS and BRAF in the plasma.
Spindler KL; Pallisgaard N; Andersen RF; Jakobsen A
Int J Cancer; 2014 Nov; 135(9):2215-22. PubMed ID: 24659028
[TBL] [Abstract][Full Text] [Related]
4. Cell-Free DNA in Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis.
Spindler KG; Boysen AK; Pallisgård N; Johansen JS; Tabernero J; Sørensen MM; Jensen BV; Hansen TF; Sefrioui D; Andersen RF; Brandslund I; Jakobsen A
Oncologist; 2017 Sep; 22(9):1049-1055. PubMed ID: 28778958
[TBL] [Abstract][Full Text] [Related]
5. Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan.
Spindler KL; Pallisgaard N; Vogelius I; Jakobsen A
Clin Cancer Res; 2012 Feb; 18(4):1177-85. PubMed ID: 22228631
[TBL] [Abstract][Full Text] [Related]
6. Total circulating cell-free DNA as a prognostic biomarker in metastatic colorectal cancer before first-line oxaliplatin-based chemotherapy.
Hamfjord J; Guren TK; Dajani O; Johansen JS; Glimelius B; Sorbye H; Pfeiffer P; Lingjærde OC; Tveit KM; Kure EH; Pallisgaard N; Spindler KG
Ann Oncol; 2019 Jul; 30(7):1088-1095. PubMed ID: 31046124
[TBL] [Abstract][Full Text] [Related]
7. RAS/BRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients.
Yao J; Zang W; Ge Y; Weygant N; Yu P; Li L; Rao G; Jiang Z; Yan R; He L; Yu Y; Jin M; Cheng G; An G
Can J Gastroenterol Hepatol; 2018; 2018():4248971. PubMed ID: 29707525
[TBL] [Abstract][Full Text] [Related]
8. Role of circulating free DNA in evaluating clinical tumor burden and predicting survival in Chinese metastatic colorectal cancer patients.
Xu X; Yu Y; Shen M; Liu M; Wu S; Liang L; Huang F; Zhang C; Guo W; Liu T
BMC Cancer; 2020 Oct; 20(1):1006. PubMed ID: 33066758
[TBL] [Abstract][Full Text] [Related]
9. Cell-free DNA in healthy individuals, noncancerous disease and strong prognostic value in colorectal cancer.
Spindler KL; Appelt AL; Pallisgaard N; Andersen RF; Brandslund I; Jakobsen A
Int J Cancer; 2014 Dec; 135(12):2984-91. PubMed ID: 24798213
[TBL] [Abstract][Full Text] [Related]
10. Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients.
Kim ST; Lee WS; Lanman RB; Mortimer S; Zill OA; Kim KM; Jang KT; Kim SH; Park SH; Park JO; Park YS; Lim HY; Eltoukhy H; Kang WK; Lee WY; Kim HC; Park K; Lee J; Talasaz A
Oncotarget; 2015 Nov; 6(37):40360-9. PubMed ID: 26452027
[TBL] [Abstract][Full Text] [Related]
11. The prognostic value of KRAS mutated plasma DNA in advanced non-small cell lung cancer.
Nygaard AD; Garm Spindler KL; Pallisgaard N; Andersen RF; Jakobsen A
Lung Cancer; 2013 Mar; 79(3):312-7. PubMed ID: 23238036
[TBL] [Abstract][Full Text] [Related]
12. Levels of cell-free DNA and plasma KRAS during treatment of advanced NSCLC.
Dowler Nygaard A; Spindler KL; Pallisgaard N; Andersen RF; Jakobsen A
Oncol Rep; 2014 Feb; 31(2):969-74. PubMed ID: 24316734
[TBL] [Abstract][Full Text] [Related]
13. KRAS mutations in tumor tissue and plasma by different assays predict survival of patients with metastatic colorectal cancer.
Xu JM; Liu XJ; Ge FJ; Lin L; Wang Y; Sharma MR; Liu ZY; Tommasi S; Paradiso A
J Exp Clin Cancer Res; 2014 Dec; 33(1):104. PubMed ID: 25491325
[TBL] [Abstract][Full Text] [Related]
14. Integrating
Ntavatzikos A; Spathis A; Patapis P; Machairas N; Peros G; Konstantoudakis S; Leventakou D; Panayiotides IG; Karakitsos P; Koumarianou A
World J Gastroenterol; 2017 Aug; 23(32):5913-5924. PubMed ID: 28932083
[TBL] [Abstract][Full Text] [Related]
15. TIMP-1 and CEA as biomarkers in third-line treatment with irinotecan and cetuximab for metastatic colorectal cancer.
Spindler KL; Christensen IJ; Nielsen HJ; Jakobsen A; Brünner N
Tumour Biol; 2015 Jun; 36(6):4301-8. PubMed ID: 25608838
[TBL] [Abstract][Full Text] [Related]
16. Circulating tumor cells (Ctc) and kras mutant circulating free Dna (cfdna) detection in peripheral blood as biomarkers in patients diagnosed with exocrine pancreatic cancer.
Earl J; Garcia-Nieto S; Martinez-Avila JC; Montans J; Sanjuanbenito A; Rodríguez-Garrote M; Lisa E; Mendía E; Lobo E; Malats N; Carrato A; Guillen-Ponce C
BMC Cancer; 2015 Oct; 15():797. PubMed ID: 26498594
[TBL] [Abstract][Full Text] [Related]
17. Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients.
Malapelle U; Mayo de-Las-Casas C; Rocco D; Garzon M; Pisapia P; Jordana-Ariza N; Russo M; Sgariglia R; De Luca C; Pepe F; Martinez-Bueno A; Morales-Espinosa D; González-Cao M; Karachaliou N; Viteri Ramirez S; Bellevicine C; Molina-Vila MA; Rosell R; Troncone G
Br J Cancer; 2017 Mar; 116(6):802-810. PubMed ID: 28170370
[TBL] [Abstract][Full Text] [Related]
18. Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie).
Huemer F; Thaler J; Piringer G; Hackl H; Pleyer L; Hufnagl C; Weiss L; Greil R
BMC Cancer; 2018 Jan; 18(1):11. PubMed ID: 29298682
[TBL] [Abstract][Full Text] [Related]
19. Clinical validation of prospective liquid biopsy monitoring in patients with wild-type RAS metastatic colorectal cancer treated with FOLFIRI-cetuximab.
Toledo RA; Cubillo A; Vega E; Garralda E; Alvarez R; de la Varga LU; Pascual JR; Sánchez G; Sarno F; Prieto SH; Perea S; Lopéz-Casas PP; López-Ríos F; Hidalgo M
Oncotarget; 2017 May; 8(21):35289-35300. PubMed ID: 27852040
[TBL] [Abstract][Full Text] [Related]
20. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
Douillard JY; Siena S; Cassidy J; Tabernero J; Burkes R; Barugel M; Humblet Y; Bodoky G; Cunningham D; Jassem J; Rivera F; Kocákova I; Ruff P; Błasińska-Morawiec M; Šmakal M; Canon JL; Rother M; Oliner KS; Wolf M; Gansert J
J Clin Oncol; 2010 Nov; 28(31):4697-705. PubMed ID: 20921465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
